PRESENT AND FUTURE OF RECOMBINANT VACCINE TECHNOLOGIES

Vaccination still has the potential to make a bigger contribution to global health. The routine uses in industrialized countries of hepatitis B and human papillomavirus vaccines successfully marked the prevention of liver and cervical cancer, is a very good example. All technological and scientific acquisitions in recombinant DNA technology over the last few years have resulted in new vaccines, thus making vaccination available to an increasing number of patients. Some recombinant vaccines have been already approved for medical use and others are in different stages of preclinical or clinical evaluation. Nowadays, novel approaches are being explored, such as: reverse vaccinology, bioconjugation technology, the use of generalized modules for membrane antigens and the use of RNA vaccines. By modifying the genome of the agents of infectious diseases new vaccines, safer, more effective, lower cost and convenient delivery, will emerge.